New Delhi: The Union Ministry of Health and Family Welfare has tightened the country’s drug approval process by introducing stricter rules against applicants who submit fake or fabricated data. The move is aimed at improving transparency and strengthening confidence in India’s drug regulatory system.
The amendments have been notified under the Drugs Rules, 1945, through G.S.R. No. 756(E) dated October 16, 2025. The new provisions work alongside the existing enforcement powers available under the Drugs and Cosmetics Act, 1940.
Stronger action against fake submissions
Until now, applicants found submitting fabricated data could face rejection of their applications or cancellation of existing licences. Under the amended rules, they may also be barred from submitting fresh applications to the concerned State or Central licensing authority for a specified period.
The new rule applies to all applications filed under the Drugs Rules, 1945. Before any action is taken, the Licensing Authority must issue a show-cause notice. Applicants will also have the right to appeal against the decision.
Why the changes matter
Drug approvals depend on scientific data submitted by manufacturers and applicants. Regulators use this information to assess the quality, safety and effectiveness of medicines before granting approvals.
The Ministry said fake or fabricated data can weaken the regulatory process, raise doubts about the quality of medicines and pose serious risks to public health. The amended rules are intended to discourage such practices and improve accountability across the pharmaceutical sector.
Aligned with global regulatory standards
According to the Ministry, the amendments are part of the government’s broader effort to strengthen India’s drug regulatory framework in line with global best practices.
The new provisions are expected to encourage manufacturers and distributors who follow regulatory standards while taking stricter action against those involved in malpractice. The reforms also support ongoing efforts to improve oversight and promote ethical practices within the pharmaceutical industry.
Focus on public confidence
The government believes reliable scientific evidence must remain the foundation of every drug approval. By introducing stronger penalties for submitting false information, the revised rules aim to protect the integrity of the approval process and reinforce public confidence in medicines available in the country.
The complete text of the notification has been published in the Official Gazette (e-Gazette) of the Government of India.